Neurosense Therapeutics is trading 7.12% up at $0.45, extending gains from the August 27 close of $0.44 and August 26 close of $0.41.
- No fresh company-specific announcement for August 28, 2026 was identified; available coverage describes no significant recent news.
- The broader market is only modestly higher, so market-wide strength does not clearly explain the move.
- Earlier PrimeC regulatory progress does not directly establish today’s cause.